Skip to content

A Comparison of Daily and Alternate-Day Prednisolone Therapy in the Treatment of Myasthenia Gravis: A pilot study

A Comparison of Daily and Alternate-Day Prednisolone Therapy in the Treatment of Myasthenia Gravis: A pilot study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240515008
Enrollment
60
Registered
2024-05-15
Start date
2024-05-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A Comparison of Daily and Alternate-Day Prednisolone Therapy in the Treatment of Myasthenia Gravis Myasthenia gravis

Interventions

Daily for Generalized MG,Daily for Ocular MG,Alternate day for Generalized MG,Alternate day for Ocular MG
Prednisolone,Prednisolone,Prednisolone,Prednisolone

Sponsors

Siriraj Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18-80 years old Patients with diagnosis of myasthenia gravis at Siriraj Hospital, Mahidol University, Bangkok, Thailand Patients who have indication for corticosteroid Generalized MG or Ocular MG that not in minimal manifestation state (MMS) after taken Pyridostigmine more than 360 mg/d

Exclusion criteria

Exclusion criteria: Patients who presented with myasthenic crisis Patients who have contraindication to corticosteroids : uncontrolled infection, uncontrolled diabetes mellitus (HbA1C 9.0), severe osteoporosis (the threshold of bone density value < -2.5 SD of T-score) Patients who are currently receiving corticosteroids treatment Body weight more than 100 Kg Patients who are Anti-MuSK Ab positive Patients who are corticosteroids, Azathioprine or Mycophenolate mofetil allergy Patients who are currently pregnancy or lactation Patients who are terminally ill Patients who have active infection including TB, HBV, HCV and HIV

Design outcomes

Primary

MeasureTime frame
To compare side effects of alternate-day prednisolone therapy and daily prednisolone therapy for myasthenia gravis 6 months body weight, infection, number of absolute lymphocyte count, fasting blood sugar (FBS), hemoglobin A1c ( HbA1C) and lipid profile; myasthenic crisis, steroid induced-exacerbation

Secondary

MeasureTime frame
To evaluate efficacy of alternate-day prednisolone therapy compared to daily therapy for myasthenia gravis treatment by 6 months days of MMS within the first 6 months after treatment, time to MMS changes in MGFA score differentiation, QOL score, and MG composite scale

Countries

Thailand

Contacts

Public ContactSantawit Jitsomboon

Faculty of Medicine Siriraj Hospital

santawit_jitsomboon@hotmail.com0894682789

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026